Relay Therapeutics

Relay Therapeutics is a clinical-stage precision medicines company based in Cambridge, Massachusetts, founded in 2016. The company specializes in drug discovery by focusing on the dynamic behavior of proteins, particularly their motion, to develop novel therapeutics. Its proprietary Dynamo™ platform combines advanced experimental techniques, such as X-ray crystallography and cryo-electron microscopy, with computational molecular dynamics simulations. This approach allows for a detailed understanding of protein motion at atomic resolution, facilitating the targeting of challenging protein targets. Relay Therapeutics is dedicated to developing therapies for precision oncology and genetic diseases. Its pipeline includes early clinical-stage drug candidates like RLY-4008, which targets FGFR2 mutations in cancers, RLY-2608 for breast cancer, and RLY-1971, developed in collaboration with Genentech to inhibit metastatic tumors. The company has established significant partnerships, including a collaboration with Genentech, which has provided funding and validation for its innovative technology. With a strong financial foundation and a focus on advancing its research and development efforts, Relay Therapeutics is positioned to make impactful contributions to the field of medicine.